Saturday, December 15, 2018 5:20:09 PM
These are some points mentioned on their factsheet.
-Investing in research to develop non-opioid pain medications.
-Delivering the US Surgeon General’s TurnTheTideRx materials, which review considerations when prescribing opioids for chronic pain, to healthcare professionals.
-Sharing the Centers for Disease Control and Prevention (CDC) Guideline for Prescribing Opioids for Chronic Pain with thousands of prescribers and pharmacists.
-Supporting the National Sheriffs’ Association (NSA) with a grant to provide front-line officers with the rescue drug naloxone.
-Working with the National Institutes of Health (NIH) as part of President Trump’s Opioid Commission on a public-private partnership focused on the development of non-addictive pain medications, innovative addition deterrent formulas and treatments for overdose.
Factsheet link
https://www.purduepharma.com/about/company-values/strong-track-record/
http://www.stockhouse.com/companies/bullboard/v.tbp/tetra-bio-pharma-inc?postid=29095650
..This situation MIGHT BE ONE OF THE REASON TETRA SP has been so seriously...bullied after each good news. Hopefully this will stop by the next summer..
FEATURED Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market • Mar 18, 2024 8:51 AM
FEATURED Prospera Energy Inc. Announces a 508% increase in the 2023 Proven Developed Producing (PDP) Reserve Valuation • Mar 18, 2024 8:09 AM
Greenlite Ventures Enters into Strategic Alliance with Woodway USA • GRNL • Mar 15, 2024 4:00 PM
HealthLynked Welcomes David Rosal as New Chief Financial Officer • HLYK • Mar 13, 2024 8:00 AM
ECGI Holdings, Inc. Announces Continued Efforts in Financial Optimization • ECGI • Mar 13, 2024 8:00 AM
PSYC Begins Business Overhaul Process with Consolidation of 10 Previously Issued Convertible Debentures • PSYC • Mar 13, 2024 7:13 AM